128 related articles for article (PubMed ID: 20432191)
1. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
Antoniu SA; Kolb MR
IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191
[TBL] [Abstract][Full Text] [Related]
2. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.
Taruneshwar Jha K; Shome A; Chahat ; Chawla PA
Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103
[TBL] [Abstract][Full Text] [Related]
5. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.
Basu D; Pal R; Sarkar M; Barma S; Halder S; Roy H; Nandi S; Samadder A
Curr Top Med Chem; 2023; 23(30):2877-2972. PubMed ID: 38164722
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Richeldi L; Costabel U; Selman M; Kim DS; Hansell DM; Nicholson AG; Brown KK; Flaherty KR; Noble PW; Raghu G; Brun M; Gupta A; Juhel N; Klüglich M; du Bois RM
N Engl J Med; 2011 Sep; 365(12):1079-87. PubMed ID: 21992121
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
Raghu G; Selman M
Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
[No Abstract] [Full Text] [Related]
11. Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
Antoniu SA
Multidiscip Respir Med; 2012 Nov; 7(1):41. PubMed ID: 23146151
[TBL] [Abstract][Full Text] [Related]
12. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
13. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
Grimminger F; Günther A; Vancheri C
Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib reduced decline in FVC in idiopathic pulmonary fibrosis.
Lake F
Ann Intern Med; 2014 Oct; 161(8):JC5. PubMed ID: 25329222
[No Abstract] [Full Text] [Related]
15. Novel treatments for idiopathic pulmonary fibrosis.
Spagnolo P
Am J Med; 2015 May; 128(5):447-9. PubMed ID: 25613299
[No Abstract] [Full Text] [Related]
16. Idiopathic pulmonary fibrosis: an update.
Spagnolo P; Sverzellati N; Rossi G; Cavazza A; Tzouvelekis A; Crestani B; Vancheri C
Ann Med; 2015 Feb; 47(1):15-27. PubMed ID: 25613170
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.
Loveman E; Copley VR; Colquitt JL; Scott DA; Clegg AJ; Jones J; O'Reilly KM; Singh S; Bausewein C; Wells A
BMC Pharmacol Toxicol; 2014 Nov; 15():63. PubMed ID: 25410822
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts WA; Antoniou KM; Borensztajn K; Costabel U; Cottin V; Crestani B; Grutters JC; Maher TM; Poletti V; Richeldi L; Vancheri C; Wells AU
Lancet Respir Med; 2014 Nov; 2(11):933-942. PubMed ID: 25439569
[TBL] [Abstract][Full Text] [Related]
19. A new hope for idiopathic pulmonary fibrosis.
Hunninghake GM
N Engl J Med; 2014 May; 370(22):2142-3. PubMed ID: 24836311
[No Abstract] [Full Text] [Related]
20. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
